Market Overview

Leerink's Takeaways From CNBC's 'Healthy Returns' Conference

Share:
Leerink's Takeaways From CNBC's 'Healthy Returns' Conference
Related AMZN
Warren Buffett's Annual Letter Is Coming This Weekend: What To Expect
Andrew Left Adds To Wayfair Short Position After Q4 Print
Trump calls Amazon's HQ2 "big loss" for NYC (Seeking Alpha)
Related CI
8 Biggest Price Target Changes For Tuesday
35 Stocks Moving In Friday's Pre-Market Session
Trustmark National Bank Trust Department Buys PIMCO Enhanced Short Maturity Active ... (GuruFocus)

The CNBC Healthy Returns Conference recently came to an end, and Leerink analyst Ana Gupte summarized the key takeaways from the event in a note on Thursday. Here’s what investors need to know:

  • According to venture capital and private equity investors, one of the largest investment opportunities in the health care space is gene therapy for the treatment of cancer, Alzheimer’s and Parkinson’s Disease. Gupte also said the health care services industry is exploding in size and scope.
  • A panel of experts said Amazon.com, Inc. (NASDAQ: AMZN) will likely take one of three paths in health care: become an aggregator of current products and services, completely disrupt the current supply chain structure or provide the underlying technology for the next generation of health care.
  • CIGNA Corporation (NYSE: CI) CEO David Cordani discussed his vision for the future of the company. “An open architecture, collaborative network approach is preferred rather than one specific, owned care delivery model,” Gupte said.
  • Technology can provide new means of diagnosis and treatment. For example, virtual reality therapy is being tested for acute and chronic pain management.
  • Modern medicine and technology is on the brink of dramatically expanding the human life expectancy, driven my new early detection methods for deadly conditions.

Leerink analyst Bradley Canino also initiated coverage of Radius Health Inc (NASDAQ: RDUS) on Thursday with an Outperform rating and $53 price target.

“Tymlos is off to a promising start, and the company is advancing a unique and proprietary transdermal patch version of the medicine,” Canino wrote.

Related Links:

Biotech Winners And Losers From Congress' Latest Funding Bill

Proteostasis Tumbles 25% After Short Seller Calls Leading Drug Candidate 'A Dud'

Latest Ratings for AMZN

DateFirmActionFromTo
Feb 2019Pivotal ResearchInitiates Coverage OnBuy
Feb 2019Raymond JamesMaintainsOutperformOutperform
Feb 2019Deutsche BankMaintainsBuyBuy

View More Analyst Ratings for AMZN
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Health Care Price Target Initiation Events Analyst Ratings Best of Benzinga

 

Related Articles (AMZN + CI)

View Comments and Join the Discussion!

Wash Trading, Bear Raiding, Cornering: The Many Forms Of Market Manipulation

'Distinctly Positioned' Las Vegas Sands Is Morgan Stanley's Top Gaming Pick